Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[THE INVESTOR] Celltrion announced Aug. 24 the Korea Intellectual Property Tribunal found Biogen’s rituximab patent invalid on Aug. 23.
The South Korean biopharmaceutical company contested the move to challenge the validity of Biogen’s patents related to its Rituxan, an original of its cancer-treatment biosimilar Truxima, in 2015.
Biogen holds three patents related to the blockbuster drug that raked in US$7.3 billion won across the world last year, and this leaves only one out of five patents related to Rituxan, a therapeutic agent for non-Hodgkin lymphoma, valid.
The favorable ruling from the patent scope confirmation trial will help accelerate Celltrion’s plan to launch the rituximab biosimilar in South Korea within this year.
By Hwang You-mee (glamazon@heraldcorp.com)
The South Korean biopharmaceutical company contested the move to challenge the validity of Biogen’s patents related to its Rituxan, an original of its cancer-treatment biosimilar Truxima, in 2015.
Biogen holds three patents related to the blockbuster drug that raked in US$7.3 billion won across the world last year, and this leaves only one out of five patents related to Rituxan, a therapeutic agent for non-Hodgkin lymphoma, valid.
The favorable ruling from the patent scope confirmation trial will help accelerate Celltrion’s plan to launch the rituximab biosimilar in South Korea within this year.
By Hwang You-mee (glamazon@heraldcorp.com)
